First Trust Capital Management L.P. purchased a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report) during the third quarter, Holdings Channel reports. The firm purchased 1,298,429 shares of the company’s stock, valued at approximately $13,218,000. Drugs Made In America Acquisition II makes up approximately 0.6% of First Trust Capital Management L.P.’s portfolio, making the stock its 20th biggest position.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Drugs Made In America Acquisition II during the 1st quarter worth approximately $19,960,000. Wealthspring Capital LLC acquired a new stake in Drugs Made In America Acquisition II in the third quarter valued at approximately $4,063,000. Kryger Capital LLC acquired a new stake in Drugs Made In America Acquisition II in the first quarter valued at approximately $3,088,000. Rivernorth Capital Management LLC acquired a new stake in Drugs Made In America Acquisition II in the first quarter valued at approximately $2,991,000. Finally, SkyView Investment Advisors LLC purchased a new position in Drugs Made In America Acquisition II in the second quarter worth $2,515,000.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on DMII. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Wall Street Zen upgraded Drugs Made In America Acquisition II to a “hold” rating in a report on Saturday, October 24th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Drugs Made In America Acquisition II has an average rating of “Sell”.
View Our Latest Analysis on DMII
Drugs Made In America Acquisition II Stock Performance
Shares of DMII stock opened at $10.24 on Monday. Drugs Made In America Acquisition II Corp. has a fifty-two week low of $9.86 and a fifty-two week high of $10.33. The stock’s 50-day simple moving average is $10.19 and its 200-day simple moving average is $10.08.
Drugs Made In America Acquisition II (NASDAQ:DMII – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported $0.07 earnings per share (EPS) for the quarter.
Drugs Made In America Acquisition II Company Profile
Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company. The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.
Featured Stories
- Five stocks we like better than Drugs Made In America Acquisition II
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding DMII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report).
Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.
